Stempeutics gets DCGI nod for phase-III clinical trial on its product for treating COVID patients Read more
Stempeutics’ allogeneic cell therapy gets DCGI approval, Cipla to market and distribute Stempeucel Read more
We are in touch with CDSCO, will submit clinical trial protocol for approval of COVID-19 treatment Read more
US patent office issued notification to grant patent to Stempeutics for its stem cell drug ‘Stempeucel’ to treat Critical Limb Ischemia Read more